- Home
- TRX vs COYA Comparison
TRX vs COYA Comparison
Compare TRX & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- COYA
- Stock Information
- Founded
- TRX 1990
- COYA 2020
- Country
- TRX Canada
- COYA United States
- Employees
- TRX N/A
- COYA N/A
- Industry
- TRX
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- TRX
- COYA Health Care
- Exchange
- TRX Nasdaq
- COYA Nasdaq
- Market Cap
- TRX 95.9M
- COYA 107.0M
- IPO Year
- TRX N/A
- COYA 2022
- Fundamental
- Price
- TRX $0.51
- COYA $6.05
- Analyst Decision
- TRX Strong Buy
- COYA Strong Buy
- Analyst Count
- TRX 1
- COYA 4
- Target Price
- TRX $1.10
- COYA $16.50
- AVG Volume (30 Days)
- TRX 1.1M
- COYA 104.1K
- Earning Date
- TRX 07-15-2025
- COYA 11-05-2025
- Dividend Yield
- TRX N/A
- COYA N/A
- EPS Growth
- TRX N/A
- COYA N/A
- EPS
- TRX N/A
- COYA N/A
- Revenue
- TRX $47,731,000.00
- COYA $423,452.00
- Revenue This Year
- TRX $23.64
- COYA N/A
- Revenue Next Year
- TRX $51.77
- COYA N/A
- P/E Ratio
- TRX $481.08
- COYA N/A
- Revenue Growth
- TRX 29.98
- COYA N/A
- 52 Week Low
- TRX $0.27
- COYA $4.65
- 52 Week High
- TRX $0.51
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- TRX 84.44
- COYA 43.93
- Support Level
- TRX $0.33
- COYA $6.05
- Resistance Level
- TRX $0.42
- COYA $6.53
- Average True Range (ATR)
- TRX 0.03
- COYA 0.48
- MACD
- TRX 0.01
- COYA -0.06
- Stochastic Oscillator
- TRX 100.00
- COYA 17.31
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.